Impact of Comorbid Psoriasis on the Efficacy of Ustekinumab and Mirikizumab in Inflammatory Bowel Disease: A Post-hoc Analysis of UNITI, SEAVUE, and LUCENT.

Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula

Abstract read

In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.Frontiers in immunology · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emily C L WongDepartment of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.

Parambir S DulaiDivision of Gastroenterology, Northwestern University, Chicago, IL, USA.

John K MarshallDepartment of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.

Vipul JairathDepartment of Medicine, Division of Gastroenterology, Western University, London, ON, Canada.

Walter ReinischDepartment of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria.

Neeraj NarulaDepartment of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada. Neeraj.narula@medportal.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD) and psoriasis (PsO) share common immunopathogenic pathways involving IL-12 and IL-23. Biologic therapies targeting these cytokines are effective for Crohn's diseasse (CD), ulcerative colitis (UC), and PsO. In patients with IBD with comorbid PsO or psoriatic arthritis (PsA), IL-12/23 or IL-23 inhibitors are preferred, however it remains unclear whether their treatment outcomes are improved compared to patients without comorbid PsO/PsA.

methodsThis post hoc analysis used patient-level data from the UNITI (CD), SEAVUE (CD), and LUCENT (UC) trials. Patients treated with ustekinumab or mirikizumab were grouped by the presence or absence of comorbid PsO and/or PsA. Clinical response, remission, and endoscopic improvement were evaluated at week 8 (CD) and week 12 (UC). Logistic regression models adjusted for covariates assessed associations between comorbid PsO/PsA and outcomes.

resultsAmong 1130 ustekinumab-treated CD patients, no significant differences were observed in week 8 clinical response (57.3 vs. 59.1%, p = 0.835) or remission (46.1 vs. 49.7%, p = 0.534) in those with vs. without PsO/PsA. Similarly, among 1849 mirikizumab-treated patients, week 12 clinical response (74.5 vs. 80.4%, p = 0.882), remission (14.9 vs. 21.3%, p = 0.385), and endoscopic improvement (25.5 vs. 30.0%, p = 0.693) were not significantly different. Logistic regression analyses confirmed no significant associations between PsO status and treatment outcomes after adjusting for covariates.

conclusionThe presence of comorbid PsO or PsA does not significantly impact the efficacy of ustekinumab in CD or mirikizumab in UC. These findings support the use of these therapies across diverse patient populations, irrespective of comorbid PsO or PsA.

Indexed as

Colitis, UlcerativeCrohn DiseaseDermatologic AgentsPsoriasisUstekinumabAdultAntibodies, Monoclonal, HumanizedComorbidityFemaleHumansMaleMiddle AgedRemission InductionTreatment OutcomeAntibodies, Monoclonal, HumanizedDermatologic AgentsmirikizumabUstekinumabCrohn’s diseaseIL-12IL-23Inflammatory bowel diseaseMirikizumabPsoriasisUlcerative colitisUstekinumab

Identifiers

PMID41712025

DOI10.1007/s10620-026-09752-6

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.